Navigation Links
VelaShape™ Helps Moms Regain their Body Confidence after Baby

VelaShape™ Helps Moms Regain their Body Confidence after Baby -- YOKNEAM, Israel and IRVINE, Calif., Oct. 19 /PRNewswire/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Cosmetics and Personal Care, Retail, Medical Equipment, Medical Pharmaceuticals, Supplementary Medicine, New Products & Services, Women-related News Click to view news release full screen  

VelaShape™ Helps Moms Regain their Body Confidence after Baby


Syneron offers special VelaBABE™ promotion in October

YOKNEAM, Israel and IRVINE, Calif., Oct. 19 /PRNewswire/ -- Syneron Medical Ltd. (Nasdaq: ELOS),, a leading medical aesthetic device innovator, is announcing their new VelaBABE™ (Vela Body After Baby Enthusiast!) promotion for women who want to reclaim their pre-baby body – with help from VelaShape™. Introduced in 2007, VelaShape is the first FDA-cleared device for cellulite and circumference reduction, to tighten and smooth trouble spots that diet and exercise can't quite fix.  Women who enter the VelaBABE promotion will have the opportunity to experience a free VelaShape treatment.  

Pregnancy is a beautiful, unforgettable experience, but during the nine months of pregnancy the body undergoes dramatic changes.  For most women, bouncing back to a pre-baby body can be difficult.  In a national survey of 500 moms conducted by M/A/R/C Research, nearly every mom agreed that their pregnancy had changed their body. According to those surveyed, the stomach and thighs were identified as major problem areas for getting back into shape after giving birth (by 85 percent and 47 percent, respectively).

"Moms are constantly juggling extra responsibilities and often put their own health on the back burner.  But even for women exercising regularly and eating well, it can be tough to tone certain areas post-pregnancy," said Lori Brightman, MD, Laser & Skin Surgery Center of New York.  "VelaShape is an easy, effective way that my patients can get rid of cellulite and tone up.  Most of my patients find that VelaShape helps boost their confidence, too, so they can spend more time enjoying motherhood instead of worrying about their thighs or tummy. The VelaBABE promotion offers a great opportunity for women across the country to see what VelaShape can do for them!"

Over 3.5 million women have already experienced VelaShape, many of whom became VelaBABEs and restored their body and reclaimed their confidence.  For more information about VelaShape, become a fan of VelaBABE on and learn more about the special promotion!

About Syneron Medical Ltd. Syneron Medical Ltd. – a company devoted to technology, science and results – is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. With its innovative approach to aesthetic treatments, Syneron has now entered into one of the largest in-demand applications, skin lightening. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The company markets and services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.

Additional information can be found at and


Any statements contained in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Further, any statements that are not statements of historical fact (including statements containing "believes," "anticipates," "plans," "expects," "may," "will," "would," "intends," "estimates" and similar expressions) should also be considered to be forward-looking statements.  There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the risk that the businesses of Syneron and Candela may not be integrated successfully; the risk that the merger transaction with Candela may involve unexpected costs or unexpected liabilities; the risk that synergies from the merger transaction may not be fully realized or may take longer to realize than expected; the risk that disruptions from the merger transaction make it more difficult to maintain relationships with customers, employees, or suppliers; as well as the risks set forth in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical Ltd. makes with the SEC from time to time.  If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.

In addition, the statements in this document reflect the expectations and beliefs of Syneron Medical Ltd. as of the date of this document.  Syneron Medical Ltd. anticipates that subsequent events and developments will cause its expectations and beliefs to change.  However, while Syneron Medical Ltd. may elect to update these forward-looking statements publicly in the future, it specifically disclaims any obligation to do so.  The forward-looking statements of Syneron Medical Ltd. do not reflect the potential impact of any future dispositions or strategic transactions that may be undertaken.  These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document.Contacts:Ashley BufordAccount Supervisor, Ruder Finn212-583-2757 Erin CarneySenior Account Executive, Ruder

SOURCE Syneron Medical Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cranewares Pharmacy ChargeLink® Version 3 Helps Improve Margins and Control Costs
2. Innovative Web-based Tool Helps Doctors Improve Care
3. Cardinal Health Helps Health Care Providers Prepare for 2010-2011 Flu Season
4. Newly Re-launched Website Helps PhDs and MDs Capitalize on Growth in Life Science Industries
5. Results of Pilot Study Published in Journal Music and Medicine Reveal The Listening Program Helps Children With Down Syndrome Improve Speech Skills
6. Innovative Partnership Helps Improve Medical Research by Optimizing Clinical Trials
7. New White Paper Helps Medical Device Manufacturers Apply New FDA Regs to Combination Products
8. Power Wheelchair From Medicare Helps Save Elderly Alabama Woman From Raging Fire That Destroyed Her Home of 40 Years
9. Exclusive Mapping Tool Helps Create Walking Communities
10. New White Paper Helps Medical Device Manufacturers Validate Cleaning Processes
11. Researchers at MD Anderson Show That Positron Emission Mammography (PEM) Helps Evaluate Early Response to Neoadjuvant Chemotherapy
Post Your Comments:
(Date:11/26/2015)... 2015 Research and Markets ( ) has ... Market Outlook to 2019 - Rise in Cardiac Disorders and ... report to their offering. Boston ... scientific and others. --> The ... Boston scientific and others. ...
(Date:11/26/2015)... -- Research and Markets ( ) has ... Horizons and Growth Strategies in the Japanese Therapeutic ... Forecasts, Competitive Intelligence, Emerging Opportunities" report to ... --> This new 247-page report provides ... monitoring market, including emerging tests, technologies, instrumentation, sales ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the Global Cell Surface Testing ... Opportunities" report to their offering.  ... the addition of the  "2016 Future ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... ... convenient way to dispense prescription medications at home, so he invented the patent-pending ... monitor and dispense prescription medications. In doing so, it could help to prevent ...
(Date:11/27/2015)... ... , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of ... than 3.7 billion people under the age of 50 – or 67% of the population ... global estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... online platform for mental health and wellness consultation, has collaborated with a leading ... bridge the knowledge gap experienced by parents and bring advice from parenting experts ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft ... announces the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite ... LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive ...
(Date:11/26/2015)... ... 2015 , ... The Catalent Applied Drug Delivery Institute today ... dose form selection in early phase drug development. The first of these is ... together the UK’s emerging life sciences companies, corporate partners, and investors, at Milton ...
Breaking Medicine News(10 mins):